Polyclonal Antibody to Apolipoprotein E (APOE) | MyBioSource MBS2004235 product information

product summary

company name :

MyBioSource

product type :

antibody

product name :

Polyclonal Antibody to Apolipoprotein E (APOE)

catalog :

MBS2004235

quantity :

0.01 mg

price :

110 USD

clonality :

polyclonal

host :

rabbit

conjugate :

nonconjugated

reactivity :

rat

application :

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation

more info or order :

MyBioSource product webpage

image

image 1 :

Western Blot: Sample: Rat Lung lysate; Primary Ab: 1ug/ml Rabbit Anti-Rat APOE Antibody Second Ab: 0.2ug/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody

image 2 :

Western Blot: Sample: Recombinant protein.

image 3 :

DAB staining on IHC-P. Samples: Rat Tissue)

product information

catalog number :

MBS2004235

products type :

Antibody

products full name :

Polyclonal Antibody to Apolipoprotein E (APOE)

products short name :

[Apolipoprotein E (APOE)]

other names :

[apolipoprotein E; Apolipoprotein E; apolipoprotein E; apolipoprotein E]

products gene name :

[APOE]

other gene names :

[Apoe; Apoe; APOEA; Apo-E]

clonality :

Polyclonal

host :

Rabbit

purity :

Antigen-specific affinity chromatography followed by Protein A affinity chromatography

form :

Supplied as solution form in PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.

concentration :

1 mg/ml

storage stability :

Storage: Avoid repeated freeze/thaw cycles. Store at 4ºC for frequent use. Aliquot and store at -20ºC for 12 months. Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

tested application :

Western Blot(WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunoprecipitation (IP).

app notes :

Western blotting: 0.5-2 ug/mL;1:500-2000. Immunohistochemistry: 5-20 ug/mL;1:50-200. Immunocytochemistry: 5-20 ug/mL;1:50-200. Optimal working dilutions must be determined by end user

image1 heading :

Western Blot (WB)

image2 heading :

Western Blot (WB)

image3 heading :

Immunohistochemistry (IHC)

other info1 :

Organism Species: Rattus norvegicus (Rat). Source: Polyclonal antibody preparation. Traits: Liquid. Immunogen: Recombinant APOE (Glu19~Arg168) expressed in E.coli

other info2 :

Conjugated Antibody: The APC conjugated antibody version of this item is also available as catalog #MBS2046350

ncbi gi num :

397529595

ncbi acc num :

NP_001257610.1

ncbi gb acc num :

NM_001270681.1

uniprot acc num :

P02650

ncbi pathways :

Alzheimer's Disease Pathway (83489); Alzheimer's Disease Pathway (509); Binding And Uptake Of Ligands By Scavenger Receptors Pathway (1376621); Cholesterol Metabolism Pathway (198522); Chylomicron-mediated Lipid Transport Pathway (1377595); HDL-mediated Lipid Transport Pathway (1377596); Lipid Digestion, Mobilization, And Transport Pathway (1377591); Lipoprotein Metabolism Pathway (1377594); Metabolism Pathway (1377550); Metabolism Of Fat-soluble Vitamins Pathway (1377745)

ncbi summary :

plays a role in plasma lipoprotein transport [RGD, Feb 2006]

uniprot summary :

APOE: Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues. Defects in APOE are a cause of hyperlipoproteinemia type 3 (HLPP3); also known as familial dysbetalipoproteinemia. Individuals with HLPP3 are clinically characterized by xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of HLPP3 have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD. Genetic variations in APOE are associated with Alzheimer disease type 2 (AD2). It is a late-onset neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease. Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known. Defects in APOE are a cause of sea-blue histiocyte disease (SBHD); also known as sea-blue histiocytosis. This disorder is characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses. Defects in APOE are a cause of lipoprotein glomerulopathy (LPG). LPG is an uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries. It mainly affects people of Japanese and Chinese origin. The disorder has rarely been described in Caucasians. Belongs to the apolipoprotein A1/A4/E family. Protein type: Lipid-binding; Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 1q21. Cellular Component: cell soma; cell surface; chylomicron; cytoplasm; dendrite; early endosome; endoplasmic reticulum; endosome; extracellular matrix; extracellular region; extracellular space; extrinsic to external side of plasma membrane; Golgi apparatus; late endosome; lysosome; membrane; microtubule; nuclear envelope; nucleus; plasma membrane. Molecular Function: amyloid-beta binding; antioxidant activity; cholesterol binding; cholesterol transporter activity; heparin binding; hydroxyapatite binding; identical protein binding; lipid binding; lipid transporter activity; low-density lipoprotein receptor binding; metal chelating activity; phospholipid binding; protein dimerization activity; protein homodimerization activity; receptor binding; tau protein binding. Biological Process: aging; amyloid precursor protein metabolic process; artery morphogenesis; axon regeneration; axon regeneration in the peripheral nervous system; cellular calcium ion homeostasis; cGMP-mediated signaling; cholesterol catabolic process; cholesterol efflux; cholesterol homeostasis; cholesterol metabolic process; fatty acid homeostasis; G-protein coupled receptor signaling pathway; lipid homeostasis; lipid metabolic process; lipid transport; lipoprotein biosynthetic process; lipoprotein catabolic process; lipoprotein metabolic process; long-chain fatty acid transport; long-term memory; maintenance of cellular localization; negative regulation of blood coagulation; negative regulation of blood vessel endothelial cell migration; negative regulation of cellular protein metabolic process; negative regulation of cholesterol biosynthetic process; negative regulation of endothelial cell proliferation; negative regulation of inflammatory response; negative regulation of MAP kinase activity; negative regulation of neuron apoptosis; neuron projection regeneration; nitric oxide mediated signal transduction; oligodendrocyte differentiation; phospholipid efflux; positive regulation of axon extension; positive regulation of cGMP biosynthetic process; positive regulation of endocytosis; positive regulation of lipid biosynthetic process; positive regulation of low-density lipoprotein particle receptor catabolic process; positive regulation of membrane protein ectodomain proteolysis; positive regulation of nitric-oxide synthase activity; protein import; protein localization; receptor-mediated endocytosis; regulation of Cdc42 protein signal transduction; regulation of cholesterol transport; regulation of gene expression; regulation of protein homooligomerization; regulation of protein metabolic process; response to dietary excess; response to ethanol; response to insulin stimulus; response to oxidative stress; response to retinoic acid; response to zinc ion; reverse cholesterol transport; triacylglycerol metabolic process; triglyceride catabolic process; vasodilation; virus assembly

size1 :

0.01 mg

price1 :

110 USD

size2 :

0.02 mg

price2 :

125

size3 :

0.05 mg

price3 :

175

size4 :

0.1 mg

price4 :

225

size5 :

0.2 mg

price5 :

330

size6 :

1 mg

price6 :

785

more info or order :

MyBioSource product webpage